Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health
- PMID: 35525727
- DOI: 10.1016/j.vaccine.2022.03.047
Impact of prior infection and repeated vaccination on post-vaccination antibody titers of the influenza A(H1N1)pdm09 strain in Taiwan schoolchildren: Implications for public health
Abstract
Background: The objective of this study was to evaluate the effects of prior-infection and repeated vaccination on post-vaccination antibody titers.
Methods: A(H1N1)pdm09 strain was included in 2009 pandemic monovalent, 2010-2011, and 2011-2012 trivalent influenza vaccines (MIVpdm09, TIV10/11, TIV11/12) in Taiwan. During the 2011-2012 influenza season, we conducted a prospective sero-epidemiological cohort study among schoolchildren from grades 1 - 6 in the two elementary schools in Taipei with documented A(H1N1)pdm09 vaccination records since 2009. Serum samples were collected at pre-vaccination, 1-month, and 4-months post-vaccination (T1, T2, T3). Anti-A(H1N1)pdm09 hemagglutination inhibition titers (HI-Ab-titers) were examined. We also investigated the impact of four vaccination histories [(1) no previous vaccination (None), (2) vaccinated in 2009-2010 season (09v), (3) vaccinated in 2010-2011 season (10v), and (4) vaccinated consecutively in 2009-2010 and 2010-2011 seasons (09v + 10v)] and pre-vaccination HI-Ab levels on post-vaccination HI-Ab responses as well as adjusted vaccine effectiveness (aVE) against serologically-defined infection from T2 to T3.
Results: TIV11/12 had zero serious adverse events reported. A(H1N1)pdm09 strain in TIV11/12 elicited seroprotective Ab-titers in 98% of children and showed promising protection (aVE: 70.3% [95% confidence interval (CI): 51.0-82.1%]). Previously unvaccinated but infected children had a 3.96 times higher T2 geometric mean titer (T2-GMT) of HI-Ab than those naïve to A(H1N1)pdm09 (GMT [95% CI]: 1039.7[585.3-1845.9] vs. 262.5[65.9-1045], p = 0.046). Previously vaccinated children with seroprotective T1-Ab-titers had a higher T2-GMT and a greater aVE than those with non-seroprotective T1-Ab-titers. Repeatedly vaccinated children had lower T2-GMT than those receiving primary doses of TIV11/12. However, after controlling prior infection and T1-Ab-titers, differences in T2-GMT among the four vaccination histories became insignificant (p = 0.16).
Conclusion: This study supports the implementation of annual mass-vaccination with A(H1N1)pdm09 in schoolchildren for three consecutive influenza seasons when vaccine and circulating strains were well matched, and found that prior infection and pre-vaccination HI-Ab levels positively impacted post-vaccination HI-Ab responses.
Keywords: A(H1N1)pdm09 virus; Antibody response; Exposure history; Inactivated influenza vaccine; Repeated vaccination; Schoolchildren; Taiwan.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Antibody responses induced by trivalent inactivated influenza vaccine among pregnant and non-pregnant women in Thailand: A matched cohort study.PLoS One. 2021 Jun 9;16(6):e0253028. doi: 10.1371/journal.pone.0253028. eCollection 2021. PLoS One. 2021. PMID: 34106994 Free PMC article.
-
The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.BMC Infect Dis. 2016 Aug 22;16(1):438. doi: 10.1186/s12879-016-1769-7. BMC Infect Dis. 2016. PMID: 27549626 Free PMC article.
-
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials.Pediatr Infect Dis J. 2015 Jul;34(7):774-82. doi: 10.1097/INF.0000000000000709. Pediatr Infect Dis J. 2015. PMID: 26069949 Clinical Trial.
-
Key points in evaluating immunogenicity of pandemic influenza vaccines: A lesson from immunogenicity studies of influenza A(H1N1)pdm09 vaccine.Vaccine. 2017 Sep 18;35(39):5303-5308. doi: 10.1016/j.vaccine.2017.07.092. Epub 2017 Aug 4. Vaccine. 2017. PMID: 28784284 Review.
-
Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis.Lancet Respir Med. 2023 Jan;11(1):27-44. doi: 10.1016/S2213-2600(22)00266-1. Epub 2022 Sep 21. Lancet Respir Med. 2023. PMID: 36152673 Free PMC article.
Cited by
-
Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2.Nat Commun. 2023 Jul 29;14(1):4575. doi: 10.1038/s41467-023-39816-4. Nat Commun. 2023. PMID: 37516771 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical